GM-CSF treatment results in increased DC populations in CTCL patients: percentages of DCs per PBMC gated on forward and side light scatter
| Patients . | GM-CSF treatment . | % CD123+ . | % CD11c+ . |
|---|---|---|---|
| 1 | No | 0.05 | 0.09 |
| Yes | 0.11 | 0.08 | |
| 2 | No | 0.07 | 0.16 |
| Yes | 0.09 | 0.18 | |
| 3 | No | 0.01 | 0.02 |
| Yes | 0.05 | 0.06 | |
| 4 | No | 0.05 | 0.04 |
| Yes | 0.09 | 0.09 | |
| 5 | No | 0.05 | 0.02 |
| Yes | 0.08 | 0.03 | |
| 6 | No | 0.04 | 0.02 |
| Yes | 0.08 | 0.12 | |
| 7 | No | 0.33 | 0.22 |
| Yes | 0.84 | 0.37 | |
| Healthy donor | — | 0.28 | 0.29 |
| Patients . | GM-CSF treatment . | % CD123+ . | % CD11c+ . |
|---|---|---|---|
| 1 | No | 0.05 | 0.09 |
| Yes | 0.11 | 0.08 | |
| 2 | No | 0.07 | 0.16 |
| Yes | 0.09 | 0.18 | |
| 3 | No | 0.01 | 0.02 |
| Yes | 0.05 | 0.06 | |
| 4 | No | 0.05 | 0.04 |
| Yes | 0.09 | 0.09 | |
| 5 | No | 0.05 | 0.02 |
| Yes | 0.08 | 0.03 | |
| 6 | No | 0.04 | 0.02 |
| Yes | 0.08 | 0.12 | |
| 7 | No | 0.33 | 0.22 |
| Yes | 0.84 | 0.37 | |
| Healthy donor | — | 0.28 | 0.29 |
Patients 1 to 6 had medium to high tumor burden; patient 7 had low tumor burden. PBMCs from healthy donors and patients before and at the end of GM-CSF treatment were viably cryopreserved in liquid nitrogen and, before assay, were recovered from liquid N2 and surface stained. PBMCs were excluded of all lineage-positive cells, whereas lineage-negative cells were analyzed for the coexpression HLA-DR and CD11c or CD123. The increase in the number of CD123+ but not CD11c+ cells during GM-CSF treatment in patients (1-6) with medium to high tumor burden was statistically significant (P < .03).